CXCR1 and metastatic malignant neoplasm: Pharmacologic targeting of the IL-8/FOXC1/CXCR1 and FOXC1/NFκB/IL-6 positive feedback loops hold promise for deriving clinical therapeutic benefit in FOXC1+ pro-metastatic cancers.